Sifalimumab, an anti-interferon-a monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.
Sifalimumab, an anti-interferon-a monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Nov; 75(11):1909-1916.
-
Adult
-
Adult
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Humanized
-
Antigens
-
Antigens
-
Cytoskeletal Proteins
-
Cytoskeletal Proteins
-
Dose-Response Relationship, Drug
-
Dose-Response Relationship, Drug
-
Double-Blind Method
-
Double-Blind Method
-
Drug Administration Schedule
-
Drug Administration Schedule
-
Female
-
Female
-
Humans
-
Humans
-
Lupus Erythematosus, Systemic
-
Lupus Erythematosus, Systemic
-
Male
-
Male
-
Membrane Proteins
-
Membrane Proteins
-
Middle Aged
-
Middle Aged
-
Oxidoreductases Acting on CH-CH Group Donors
-
Oxidoreductases Acting on CH-CH Group Donors
-
Proteins
-
Proteins
-
Severity of Illness Index
-
Severity of Illness Index
-
Treatment Outcome
-
Treatment Outcome